PEPTONIC Medical AB: The subscription price for warrants of series TO6 in Peptonic has been determined to SEK 0.0011 and the exercise period begins today
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
Peptonic Medical AB ("Peptonic" or the "Company") completed during the first quarter of 2026 a rights issue of units, consisting of shares and warrants of series TO6 (the "Warrants" or "TO6"). The subscription price for the Warrants has been determined to SEK 0.0011 per share, which corresponds to 70 percent of the volume-weighted average price in the Company's share on Spotlight Stock Market during the measurement period, which ran from May 18, 2026, up to and including May 29, 2026. One (1) Warrant entitles the holder to subscribe for one (1) new share in the Company from today, June 1, 2026, up to and including June 12, 2026.
Today, June 1, 2026, the exercise period for TO6 begins. Each TO6 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.0011. The subscription price for the Warrants corresponds to 70 percent of the volume-weighted average price in the Company's share on Spotlight Stock Market during the measurement period, which ran from May 18, 2026, up to and including May 29, 2026. Full terms and conditions for TO6 are available on the Company's website: www.peptonicmedical.se.
If all TO6 are exercised, the Company will receive approximately SEK 12.5 million before issuance costs. To avoid the TO6 expiring without value, it is required that the holder actively exercise TO6 to subscribe for new shares in the Company no later than June 12, 2026, or dispose of the Warrants no later than June 9, 2026. Please note that certain nominees may close their subscription process earlier than June 12, 2026.
The outcome of the exercise of the Warrants is intended to be announced via a press release on or about June 15, 2026.
Summarized terms for TO6:
Exercise period: June 1, 2026 - June 12, 2026.
Issue size: 11,387,158,200 TO6, which entitles to subscription of 11,387,158,200 shares. If all TO6 are exercised, the Company will receive approximately SEK 12.5 million before issuance costs.
Exercise price: SEK 0.0011 per share.
Last day for trading in TO6: June 9, 2026.
Share capital and dilution: If all TO6 are exercised the share capital will increase with approximately SEK 1,138,715.8200, from approximately SEK 2,072,456.7314 to approximately SEK 3,211,172.5514. If all TO6 are exercised the number of shares in the Company will increase with 11,387,158,200 shares, from 20,724,567,314 shares to 32,111,725,514 shares. If all TO6 are exercised, the dilution amounts to approximately 35.46 percent of the existing number of shares and votes in the Company.
Please note that TO6 that are not exercised on or before June 12, 2026, or disposed of on or before June 9, 2026, will expire without value. For TO6 not to expire without value, the holder must actively subscribe for shares by exercise of the Warrants, or alternatively dispose of the Warrants.
How TO6 are exercised:
Nominee-registered TO6 (Custody account)
Subscription and payment by exercise of TO6 shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered TO6 (Securities account)
No issue statement or payment instructions will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. TO6 will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company's website, www.peptonicmedical.se, and on Mangold Fondkommission AB's website, www.mangold.se.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of TO6.
For further information, please contact:
Daniel Rudeklint, interim CEO Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73
About PEPTONIC medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in intimate women's health. Under the brands VagiVital and Vernivia, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common medical conditions in the genital area. Peptonic's growth strategy is based on geographic expansion, especially in the US and Europe, and on continuously strengthening the product portfolio through its own product development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the United States. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, Russia, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.